First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.

3076 Background: ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Over-expression of Eg5 causes genomic instabili...